Results
1 -
8 of
8
(Click
here to explore results)
- Pericytes and shear stress each alter the shape of a self-assembled vascular network. Kazuya Fujimoto, Scott Erickson, Masamune Nakayama, Hiroki Ihara, Kei Sugihara, Yuji Nashimoto, Koichi Nishiyama, Takashi Miura, Ryuji Yokokawa
, Lab Chip
, 2023
, 23
, 306
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. Baku Acharya, Debasmita Saha, Daniel Armstrong, Naga Rajiv Lakkaniga, Brendan Frett
, RSC Med. Chem.
, 2022
, 13
, 798
- Synthesis of benzimidazole/triphenylamine-based compounds, evaluation of their bioactivities and an in silico study with receptor tyrosine kinases. Mani Arulkumar, Kai Yang, Neng Wang, Sakayanathan Penislusshiyan, Thayumanavan Palvannan, Karthick Ramalingam, Fuming Chen, Shi-He Luo, Yong-Jun Zhou, Zhao-Yang Wang
, New J. Chem.
, 2022
, 46
, 675
- Sustainable methine sources for the synthesis of heterocycles under metal- and peroxide-free conditions. Gopal Chandru Senadi, Vishal Suresh Kudale, Jeh-Jeng Wang
, Green Chem.
, 2019
, 21
, 979
- The design and synthesis of potent benzimidazole derivatives via scaffold hybridization and evaluating their antiproliferative and proapoptotic activity against breast and lung cancer cell lines. Mohamed Saleh Elgawish, Mohamed S. Nafie, Asmaa S. A. Yassen, Koji Yamada, Nagat Ghareb
, New J. Chem.
, 2022
, 46
, 4239
- Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase. Thales Souza Freire, Ignez Caracelli, Julio Zukerman-Schpector, Ran Friedman
, Phys. Chem. Chem. Phys.
, 2023
, 25
, 6175
- Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Haonan Li, Qiang Luo, Hu Zhang, Xuelei Ma, Zhongwei Gu, Qiyong Gong, Kui Luo
, Chem. Soc. Rev.
, 2023
, 52
, 47
- Design, synthesis, and biological evaluation with molecular dynamics study of novel pyrazolo[3,4-d]pyrimidine derivatives as anti-cancer agents. Rania M. Shaban, Nermin Samir, Yassin M. Nissan, Khaled A. M. Abouzid
, RSC Adv.
, 2023
, 13
, 17074